Chemotherapy May be Preferable Option in NSCLC with Wild Type EGFR

“Chemotherapy yielded improved PFS vs. treatment using epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non–small cell lung cancer with wild-type epidermal growth factor receptor.

“However, researchers noted that chemotherapy did not confer a benefit over EGFR TKIs in terms of OS.

“In the meta-analysis, researchers conducted a literature search of several scientific databases, including PubMed, Embase, Cochrane database, and abstracts from meetings of the American Society of Clinical Oncology and the European Society of Medical Oncology.”

Editor’s note: The study described here compared chemotherapy to treatment with targeted therapy drugs called EGFR TKIs for patients with non-small cell lung cancer (NSCLC) whose tumors did NOT have mutations in the EGFR gene. (EGFR mutations and other mutations are often tested to help determine patients’ treatment options.) The scientists found that chemotherapy  may be a better option for these patients. Chemotherapy seemed to extend the time that patients lived without their disease worsening. However, it did not show any benefit over EGFR TKIs in terms of overall survival.